title: Update on hepatitis C: Direct-acting antivirals.
abstract: Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.
authors.affiliation: Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Leon L
authors.initials: LL
authors.lastname: Seifert
authors.affiliation: Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Ryan B
authors.initials: RB
authors.lastname: Perumpail
authors.affiliation: Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Aijaz
authors.initials: A
authors.lastname: Ahmed
keywords: Direct-acting antivirals; Hepatitis C virus; Management; Sustained virologic response; Treatment